Join our daily newsletter At The Bell to receive exclusive market insights
Good Afternoon and welcome to HotCopper Highlights for Week 3 of 2026, I’m Jon Davidson. In this segment the stocks and announcements generating the most attention on Australia’s #1 finance website, the HotCopper forums. Let’s launch straight into it starting with the most viewed.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Electro Optic Systems back on radars this week, no pun intended, after the stock purchased a counterdrone company whose technology sees AI-powered high-calibre machine guns capable of spotting and shooting down drones quicker than a human can; this is obviously in my mind at least a run at Droneshield’s market share.
Meanwhile, Unity Metals gaining some attention on the forums this week; I’ve chosen that stock because it’s the first IPO of 2026 and so far reception has been lacklustre. That might be because while the company will soon be drilling for gold, it’s doing it in Cambodia – a jurisdiction not without its risks.
Finally, BHP Ltd catching eyes as the company’s share price heads towards $50 dollars each, putting it more or less at the same valuation as Mag1 stock Commonwealth Bank. But with Australia’s economy based on rocks and houses, that’s probably not too surprising.
And as for the most discussed?
4D Medical back on the most popular list after this week launching a capital raising at $3.80 a share via Bell Potter to net $150M, astonishingly, the market rewarded the raise with shares trading a dollar higher at $4.80 on Friday. If that seems frothy to you, it’s because it is – though many investors are bullish big dollar contracts aren’t far away.
GreenX Metals meanwhile getting speculation rolling as a trade court in Singapore determined that the government of Poland does owe the company $400M over the closure of two coal mines a few years back, GreenX metals of course wasn’t called ‘GreenX Metals’ when it was dealing with coal.
Finally, stem cell drugmaker Mesoblast reapproaching darling status as the US-based company sees sales of its drug Ryoncil continuing to grow, evidence perhaps that the great stem cell market mightn’t be such a pipe dream in the modern world.
That’s Market Close for Week 3, I’m Jon Davidson, have a great weekend and we’ll see you on Monday.
Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.
